Elizabeth Sally Ward FRS is a British scientist who is Director of Translational Immunology at the Centre for Cancer Immunology in the University of Southampton.[1][2] She was elected Fellow of the Royal Society in 2022.[3]
Sally Ward | |
|---|---|
| Born | Elizabeth Sally Ward |
| Alma mater | University of Cambridge |
| Awards | Royal Society Wolfson Research Merit Award (2018) |
| Scientific career | |
| Fields | Immunology Cancer Biology Antibody Engineering Antibody Therapeutics[1] |
| Institutions | Texas A&M University University of Texas Southwestern Medical Center University of Cambridge University of Southampton |
| Thesis | Molecular genetics of an insectidal delta-endotoxin from Bacillus thuringiensis var israelensis. (1985) |
| Doctoral advisor | David J. Ellar |
| Website | www |
Early life and education
editWard was an undergraduate student at the University of Cambridge, where she studied the Natural Sciences Tripos with a focus on biochemistry. She remained at Cambridge for her doctoral research, working under the supervision of David J. Ellar at Gonville and Caius College, Cambridge.[4][5][6] Her PhD research investigated the genetics of delta endotoxin from Bacillus thuringiensis israelensis.[7]
Research and career
editWard remained at Cambridge as a junior research fellow, working in both Gonville and Caius College and Sidney Sussex College, Cambridge.[8]
In 1990, Ward moved to the United States. She joined the University of Texas Southwestern Medical Center, where she was a member of the founding team of the Centre for Immunology. She was awarded various named chairs in Texas, including the Paul and Betty Meek-FINA Professorship. In 1996, Ward identified the Fc receptor, a regulator of Immunoglobulin G levels.[9] She moved to the Texas A&M University Health Sciences University in 2014.[9] In 2018, Ward returned to the United Kingdom, joining the University of Southampton as Professor of Molecular Immunology and Director of Translational Immunology.[10][11]
Ward works on antibody and protein engineering to treat autoimmune disease.[12] She makes use of in vivo studies to design novel anti-body therapies for the treatment of cancer. Her early identification of the Fc receptor has resulted in the development of FcRn antagonist technologies.[13][14] Ward has licensed these Abdegs (antibodies that enhance IgG degradation) to the pharmaceutical industry, resulting in anti-body therapeutics.[9][14][15]
Ward has developed advanced microscopies and image analysis techniques. She has demonstrated single molecule spectroscopy is capable of imaging single protein molecules at exceptional resolution. She uses multi-colour imaging to interrogate the cell surfaces. Using these approaches, Ward visualised the biological pathways intracellular endoscopes to the plasma membrane (and vice versa).[12] She has also pioneered open access software packages for miroscopy analysis.[12]
Awards and honours
edit- 2018 Royal Society Wolfson Research Merit Award[citation needed]
- 2020 Elected Vice President of the Antibody Society[9]
- 2022 Elected Fellow of the Royal Society[3]
Selected publications
edit- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli[16]
- Localization accuracy in single-molecule microscopy"[17]
- Multiple roles for the major histocompatibility complex class I- related receptor FcRn[18]
- Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies[19]
References
edit- ^ a b E. Sally Ward publications indexed by Google Scholar
- ^ E. Sally Ward publications from Europe PubMed Central
- ^ a b Anon (2022). "Sally Ward FRS". royalsociety.org. London: Royal Society. Retrieved 2022-05-11.
- ^ Anon (2020). "Professor David Ellar (1939 - 2020)". cai.cam.ac.uk.
- ^ Susana Vilchez (3 December 2020). "A Tribute to a <i>Bacillus thuringiensis</i> Master: Professor David J. Ellar". Toxins. 12 (12). doi:10.3390/TOXINS12120764. ISSN 2072-6651. PMID 33287128. Wikidata Q104108938.
- ^ Anon (2018). "Cancer Institute Seminar Series - Prof Sally Ward". ucl.ac.uk. UCL Cancer Institute. Retrieved 2022-05-11.
- ^ Ward, Elizabeth Sally (1985). Molecular genetics of an insectidal delta-endotoxin from Bacillus thuringiensis var israelensis. cam.ac.uk (PhD thesis). University of Cambridge. OCLC 499855244. EThOS uk.bl.ethos.377842.
- ^ Anon. "Home". wardoberlab.com. WardOber Lab. Retrieved 2022-05-11.
- ^ a b c d "Sally Ward, Ph.D." antibodysociety.org. The Antibody Society. Retrieved 2022-05-11.
- ^ Anon (2019). "Lab Members". wardoberlab.com. WardOber Lab. Retrieved 2022-05-11.
- ^ "Interview with Sally Ward and Raimund Ober". southampton.ac.uk. Centre for Cancer Immunology. Retrieved 2022-05-11.
- ^ a b c Anon (2019). "Research Interests". wardoberlab.com. Retrieved 2022-05-11.
- ^ "SELECTBIO - High-Content and Phenotypic Screening Europe 2018 Speaker Biography". selectbiosciences.com. Retrieved 2022-05-11.
- ^ a b "More than two decades of UTSW research paves way for first-in-kind drug". utsouthwestern.edu. 3 January 2022. Retrieved 2022-05-11.
- ^ "Married scientists developing breakthrough cancer drugs urge people to Stand Up To Cancer". dailyecho.co.uk. Daily Echo. 14 October 2021. Retrieved 2022-05-11.
- ^ Ward ES; Güssow D; Griffiths AD; Jones PT; Winter G (1 October 1989). "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli". Nature. 341 (6242): 544–546. doi:10.1038/341544A0. ISSN 1476-4687. PMID 2677748. Wikidata Q35896400.
- ^ Raimund J. Ober; Sripad Ram; E. Sally Ward (1 February 2004). "Localization accuracy in single-molecule microscopy". Biophysical Journal. 86 (2): 1185–1200. doi:10.1016/S0006-3495(04)74193-4. ISSN 0006-3495. PMC 1303911. PMID 14747353. Wikidata Q34184690.
- ^ Ghetie V; Ward ES (1 January 2000). "Multiple roles for the major histocompatibility complex class I- related receptor FcRn". Annual Review of Immunology. 18: 739–766. doi:10.1146/ANNUREV.IMMUNOL.18.1.739. ISSN 0732-0582. PMID 10837074. Wikidata Q33932754.
- ^ Ober RJ; Radu CG; Ghetie V; Ward ES (1 December 2001). "Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies". International Immunology. 13 (12): 1551–1559. doi:10.1093/INTIMM/13.12.1551. ISSN 0953-8178. PMID 11717196. Wikidata Q34102657.